STING1 and neoplasm: The combined immunotherapy of STING agonist with anti-PD-1/PD-L1 can neutralize the immunosuppressive effects of STING agonists (i.e. PD-L1 upregulation), delay tumor growth and protect against tumor rechallenge in mice [300, 301].